New diabetes drug put to the test: will it mess with birth control?
NCT ID NCT06513104
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 1 trial looked at whether a new experimental drug called NNC0519-0130 changes how the body processes a common birth control pill (ethinylestradiol and levonorgestrel) and how fast the stomach empties. Forty-seven healthy postmenopausal women took part. The goal is to understand potential drug interactions before testing the drug in people with type 2 diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC0519-0130
What this could lead to
If successful, this study could help ensure that future diabetes treatments do not interfere with birth control pills or digestion.
What could go wrong
This is an early phase 1 study in a small group of healthy volunteers, not patients. Results may not apply to people with diabetes or other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Parexel International GmbH
Berlin, 14050, Germany